Bristol-Myers Squibb Company BMY NYSE

Bristol-Myers Squibb Company (BMY) reported total assets of $90.04B and total liabilities of $71.53B for quarter ending 2025-12-31, resulting in total equity of $18.51B.

The company held $10.67B in cash and short-term investments. Total debt stood at $47.14B, with net debt of $36.93B. The Debt-to-Equity (D/E) ratio was 2.55 (leveraged).

Current ratio is 1.26, suggesting adequate short-term liquidity. Interest coverage is 27.8x (strong).

Criteria supported by this page:

• HEALTH (50/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (75/100) — Total assets $90.04B and equity $18.51B support the company's competitive scale
• VALUE (69/100) — Debt-to-Equity 2.55 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 56/100 with 2/7 criteria passed.